CHRONIC GRAFT VERSUS HOST DISEASE

This early-phase study tests whether adding fostamatinib to the standard drug ruxolitinib is safe and effective for people with chronic graft-versus-host disease (cGVHD) that does not respond well to steroids. cGVHD is a complication after a stem cell transplant where the donor c…

This study tests a new drug called axatilimab against the best available treatments for children aged 2 to 17 with chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell transplant. Participants must have already tried at least two prior treatments. T…

This study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) due to chronic graft-versus-host disease after a donor stem cell transplant. The drug targets immune cells that cause inflammation and scarring. About 50 adults will receive the tre…

This study tests whether combining the drug axatilimab with a blood-filtering treatment called ECP can help people with chronic graft-versus-host disease (cGVHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. About 49 participants …

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study tests a drug called belumosudil for people who develop a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The goal is to see if the drug can improve lung function or slow the disease. About 45 participants with new or early-stage…

This study is for Chinese patients with chronic graft-versus-host disease (cGVHD) that has not improved with standard treatments. The purpose is to test the safety and effectiveness of a drug called axatilimab. About 30 participants aged 12 and older will receive the drug, and re…

This study tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 120 participants aged 12 and older will receiv…

This study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplants where the donor's immune cells attack the patient's body. About 82 participants will receive either belumosudil or a placebo. The…

This study tests whether adding axatilimab to standard steroids helps people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 240 participants aged 12 and older will receive either axatilimab or a placebo, plus st…

This early-stage trial tests an experimental drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. cGVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The main goal…

This study tests a combination of two drugs, belumosudil and rituximab, as the first treatment for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The goal is to see if this approach can control the disease and reduce the need f…

This study tests a drug called belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The disease has not improved with at least two prior treatments. The goal is to find the right dose and see if t…

This study tests whether the drug ibrutinib can prevent chronic graft-versus-host disease (GVHD) in people who have received a donor stem cell transplant. About 40 adults who are 50 to 110 days post-transplant will take ibrutinib to block certain immune cells that cause GVHD. The…

This study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body. About 45 adults receiving a stem cell transplant for blood cancer will get a post…

This study looks at whether a home-based exercise program (aerobic and resistance training) is practical and helpful for adults who develop graft-versus-host disease after a stem cell transplant and are starting high-dose steroids. About 36 participants will either do the exercis…

This study looks at whether crushing belumosudil tablets affects how the drug is absorbed in people with chronic graft-versus-host disease (cGVHD). Eight adults who have had a stem cell transplant will take the drug as a whole tablet and later as a crushed tablet in water. The go…

This study enrolls 300 adults with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Researchers collect blood samples and clinical data before and after treatment to look for changes that might predict how well someone will respond. The goal is to b…